Less Than Half of Stroke Discharges Prescribed a Statin

Share this content:
Less Than Half of Stroke Discharges Prescribed a Statin
Less Than Half of Stroke Discharges Prescribed a Statin

WEDNESDAY, Aug. 2, 2017 (HealthDay News) -- Less than half of ischemic stroke patients discharged from the hospital receive a prescription for statins, according to a study published online Aug. 2 in the Journal of the American Heart Association.

Using medical records from 2003 to 2013, Karen C. Albright, Ph.D., D.O., from the Birmingham VA Medical Center in Alabama, and colleagues analyzed discharge medications for participants hospitalized for an ischemic stroke as part of follow-up during the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study.

The researchers restricted analyses to 323 of the 666 patients with incident stroke who were not statin users at the time of admission and had no history of atrial fibrillation. Just 48.7 percent were prescribed a statin on discharge. Participants aged 65 years and older living in the Stroke Belt were 47 percent less likely to be discharged on a statin compared with those younger than 65 years (relative risk [RR], 0.53; 95 percent confidence interval [CI], 0.38 to 0.74). This association was not seen in non-Stroke Belt residents. Blacks were more likely than whites to be discharged on a statin outside the Stroke Belt (RR, 1.42; 95 percent CI, 1.04 to 1.94), but no racial association was present among Stroke Belt residents (RR, 0.93; 95 percent CI, 0.69 to 1.26; P for interaction = 0.228). Men in the Stroke Belt were 31 percent less likely to be discharged on a statin than women (RR, 0.69; 95 percent CI, 0.50 to 0.94). However, men outside the Stroke Belt were more likely to be discharged on a statin (RR, 1.38; 95 percent CI, 0.99 to 1.92; P for interaction = 0.004).

"Statin discharge prescribing may differ among Stroke Belt and non-Stroke Belt residents, particularly in older Americans and men," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »